The epidermal growth factor receptor-tyrosine kinase: A promising therapeutic target in solid tumors

被引:156
作者
Ritter, CA
Arteaga, CL
机构
[1] Vanderbilt Univ, Sch Med, Div Hematol Oncol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA
[4] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA
关键词
D O I
10.1053/sonc.2003.50027
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:3 / 11
页数:9
相关论文
共 71 条
  • [1] Agus DB, 2000, SEMIN ONCOL, V27, P53
  • [2] Development of inhibitors for protein tyrosine kinases
    Al-Obeidi, FA
    Lam, KS
    [J]. ONCOGENE, 2000, 19 (49) : 5690 - 5701
  • [3] Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition
    Albanell, J
    Rojo, F
    Averbuch, S
    Feyereislova, A
    Mascaro, JM
    Herbst, R
    LoRusso, P
    Rischin, D
    Sauleda, S
    Gee, J
    Nicholson, RI
    Baselga, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 110 - 124
  • [4] ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression
    Anderson, NG
    Ahmad, T
    Chan, K
    Dobson, R
    Bundred, NJ
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (06) : 774 - 782
  • [5] Arteaga CL, 2001, J CLIN ONCOL, V19, p32S
  • [6] The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer
    Bartlett, JMS
    Langdon, SP
    Simpson, BJB
    Stewart, M
    Katsaros, D
    Sismondi, P
    Love, S
    Scott, WN
    Williams, ARW
    Lessells, AM
    Macleod, KG
    Smyth, JF
    Miller, WR
    [J]. BRITISH JOURNAL OF CANCER, 1996, 73 (03) : 301 - 306
  • [7] ZD1839 ('Iressa')1,2 as an anticancer agent
    Baselga, J
    Averbuch, SD
    [J]. DRUGS, 2000, 60 (Suppl 1) : 33 - 40
  • [8] Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
    Baselga, J
    Pfister, D
    Cooper, MR
    Cohen, R
    Burtness, B
    Bos, M
    D'Andrea, G
    Seidman, A
    Norton, L
    Gunnett, K
    Falcey, J
    Anderson, V
    Waksal, H
    Mendelsohn, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) : 904 - 914
  • [9] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
    Baselga, J
    Rischin, D
    Ranson, M
    Calvert, H
    Raymond, E
    Kieback, DG
    Kaye, SB
    Gianni, L
    Harris, A
    Bjork, T
    Averbuch, SD
    Feyereislova, A
    Swaisland, H
    Rojo, F
    Albanell, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) : 4292 - 4302
  • [10] Type I Receptor Tyrosine Kinases as Targets for Therapy in Breast Cancer
    Baselga, Jose
    Mendelsohn, John
    [J]. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 1997, 2 (02) : 165 - 174